Who are STSP-0601 for Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SL1002, GC3107, SIM0718 Injection, MG1111 (Barycela inj.).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/stsp-0601-for-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

STSP-0601 for Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

STSP-0601 for Injection (STSP-0601 for Injection) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha fusion protein. Area: Virology/Immunology.

phase 3 Interferon alpha fusion protein Interferon alpha receptor (IFNAR) Virology/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

STSP-0601 for Injection (STSP-0601 for Injection) — Staidson (Beijing) Biopharmaceuticals Co., Ltd. STSP-0601 is a recombinant human serum albumin-interferon alpha fusion protein that enhances antiviral and immunomodulatory responses.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
STSP-0601 for Injection TARGET	STSP-0601 for Injection	Staidson (Beijing) Biopharmaceuticals Co., Ltd	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
SL1002	SL1002	Saol Therapeutics Inc	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
GC3107	GC3107	Green Cross Corporation	phase 3	Interferon alpha fusion protein	Type I interferon receptor (IFNAR)
SIM0718 Injection	SIM0718 Injection	Simcere Pharmaceutical Co., Ltd	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)
MG1111 (Barycela inj.)	MG1111 (Barycela inj.)	GC Biopharma Corp	phase 3	Interferon alpha fusion protein	Interferon alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha fusion protein class)

GC Biopharma Corp · 1 drug in this class
Green Cross Corporation · 1 drug in this class
Saol Therapeutics Inc · 1 drug in this class
Simcere Pharmaceutical Co., Ltd · 1 drug in this class
Staidson (Beijing) Biopharmaceuticals Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). STSP-0601 for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/stsp-0601-for-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing